In contrast, in ovarian cancer patients, higher levels of FBXL7 transcripts correlate with worse overall survival and progression-free survival and also predict a higher risk of recurrence after adjuvant chemotherapy [35]. Here, FBXL7 is linked to ovarian carcinoma.